Jones et al JCO 2005
Docetaxel vs paclitaxel in 1L
•
Multicenter phase III RCT: Docetaxel
100
vs paclitaxel
175
q3w
•
Total N=449
•
Any CT for MBC 58.2 vs 52.7% (almost 98% previous anthras)
•
>85% postM; 56 vs 50% ER/PR positive (>50% previous HT)
•
Primary endpoint: ORR and toxicity (secondary: TTP, DoR, OS, QoL
•
Docetaxel superior to paclitaxel in terms of OS and TTP
•
ORR higher for docetaxel (NS)
•
Hematologic and non-hematologic toxicities occurred more frequently in the docetaxel group & global QoL scores
were similar for both agents over time
Arm ORR
DoR*
TTP*
OS*
Doce 32%
7.5 mo
5.7 mo 15.4 mo
Pacli 25%
4.6mo
3.6 mo 12.7 mo
- In assessable population, ORR higher for doce (37%
vs
26%*) & median DoR (7.5
vs
4.6 mo*)
*Doce (N=189 from 225) and pacli (N=205 from 224)
